Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger B Cohen

Showing results (1-10 of 208) with videos related to

Pageof 21
Sort By:
Cancer Treatment Reviews|November 13, 2013
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)Roger B Cohen
Clinical Colorectal Cancer|March 7, 2003
Epidermal growth factor receptor as a therapeutic target in colorectal cancerRoger B Cohen
JAMA Otolaryngology-- Head & Neck Surgery|December 8, 2022
Problems With Interpreting Treatment Effects in Observational Competing Risks Data-ReplyLova Sun, Roger B Cohen
Hematology/Oncology Clinics of North America|November 18, 2008
New agents in the treatment for malignancies of the salivary and thyroid glandsRanee Mehra, Roger B Cohen
Investigational New Drugs|February 14, 2012
Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicitiesRoger B Cohen, Stéphane Oudard
Current Cancer Drug Targets|November 30, 2007
EGFR-targeting monoclonal antibodies in head and neck cancerIgor Astsaturov, Roger B Cohen, Paul Harari
Expert Review of Anticancer Therapy|October 6, 2006
Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancerIgor Astsaturov, Roger B Cohen, Paul Harari
JACC. Cardiooncology|August 16, 2021
Immune Checkpoint Inhibitor-Related Cardiovascular Toxicity in Lung Cancer: Is Routine Screening Indicated?Lova Sun, Charu Aggarwal, Roger B Cohen
Expert Opinion on Drug Metabolism & Toxicology|January 18, 2012
Pharmacokinetic evaluation of axitinibBrian Patson, Roger B Cohen, Anthony J Olszanski
JCO Precision Oncology|March 26, 2019
Targeting HER2/neu Oncogene Overexpression With Ado-Trastuzumab Emtansine in the Treatment of Metastatic Salivary Gland Neoplasms: A Single-Institution ExperienceBrandon L Swed, Roger B Cohen, Charu Aggarwal
Pageof 21

Showing results (1-10 of 208) with videos related to

Sort By:
Pageof 21
Cancer Treatment Reviews|November 13, 2013
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)Roger B Cohen
Clinical Colorectal Cancer|March 7, 2003
Epidermal growth factor receptor as a therapeutic target in colorectal cancerRoger B Cohen
JAMA Otolaryngology-- Head & Neck Surgery|December 8, 2022
Problems With Interpreting Treatment Effects in Observational Competing Risks Data-ReplyLova Sun, Roger B Cohen
Hematology/Oncology Clinics of North America|November 18, 2008
New agents in the treatment for malignancies of the salivary and thyroid glandsRanee Mehra, Roger B Cohen
Investigational New Drugs|February 14, 2012
Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicitiesRoger B Cohen, Stéphane Oudard
Current Cancer Drug Targets|November 30, 2007
EGFR-targeting monoclonal antibodies in head and neck cancerIgor Astsaturov, Roger B Cohen, Paul Harari
Expert Review of Anticancer Therapy|October 6, 2006
Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancerIgor Astsaturov, Roger B Cohen, Paul Harari
JACC. Cardiooncology|August 16, 2021
Immune Checkpoint Inhibitor-Related Cardiovascular Toxicity in Lung Cancer: Is Routine Screening Indicated?Lova Sun, Charu Aggarwal, Roger B Cohen
Expert Opinion on Drug Metabolism & Toxicology|January 18, 2012
Pharmacokinetic evaluation of axitinibBrian Patson, Roger B Cohen, Anthony J Olszanski
JCO Precision Oncology|March 26, 2019
Targeting HER2/neu Oncogene Overexpression With Ado-Trastuzumab Emtansine in the Treatment of Metastatic Salivary Gland Neoplasms: A Single-Institution ExperienceBrandon L Swed, Roger B Cohen, Charu Aggarwal
Pageof 21